373 related articles for article (PubMed ID: 22644772)
1. A prospective open-label clinical trial of efficacy of the every week administration of adalimumab in the treatment of hidradenitis suppurativa.
Sotiriou E; Goussi C; Lallas A; Chovarda E; Apalla Z; Lazaridou E; Ioannides D
J Drugs Dermatol; 2012 May; 11(5 Suppl):s15-20. PubMed ID: 22644772
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
3. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Amano M; Grant A; Kerdel FA
Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
[TBL] [Abstract][Full Text] [Related]
4. An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa.
Giamarellos-Bourboulis EJ; Pelekanou E; Antonopoulou A; Petropoulou H; Baziaka F; Karagianni V; Stavrianeas N; Giamarellou H
Br J Dermatol; 2008 Mar; 158(3):567-72. PubMed ID: 18076705
[TBL] [Abstract][Full Text] [Related]
5. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
[TBL] [Abstract][Full Text] [Related]
6. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
[TBL] [Abstract][Full Text] [Related]
7. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
[TBL] [Abstract][Full Text] [Related]
8. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
9. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
10. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients.
Fardet L; Dupuy A; Kerob D; Levy A; Allez M; Begon E; Bachelez H; Morel P; Lebbé C
J Am Acad Dermatol; 2007 Apr; 56(4):624-8. PubMed ID: 17240478
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
Mekkes JR; Bos JD
Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
[TBL] [Abstract][Full Text] [Related]
13. Etanercept: effective in the management of hidradenitis suppurativa.
Cusack C; Buckley C
Br J Dermatol; 2006 Apr; 154(4):726-9. PubMed ID: 16536817
[TBL] [Abstract][Full Text] [Related]
14. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
[TBL] [Abstract][Full Text] [Related]
15. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
16. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
18. Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
Ann Intern Med; 2012 Dec; 157(12):I-50. PubMed ID: 23247950
[No Abstract] [Full Text] [Related]
19. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.
Vender R
J Drugs Dermatol; 2011 Apr; 10(4):396-402. PubMed ID: 21455550
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
